(redirected from 17-Hydroxyprogesterone)
Also found in: Wikipedia.


A compound produced by the adrenal glands and often used therapeutically as a progestogen when such a steroid is needed for parenteral administration.
References in periodicals archive ?
Biochemical profiles include 17-hydroxyprogesterone, serum electrolytes, androgen, anti-Mullerian hormone (AMH), gonadotropin levels, hCG and ACTH stimulation tests.
This primary endpoint is similar to an endpoint previously reported in the Phase II clinical trial, where the data showed a significant reduction in the morning levels of 17-hydroxyprogesterone (the main androgen) in patients after six months on Chronocort (median 70nmol/l vs 5.
Gonadotrophins, 17-hydroxyprogesterone (17OHP), dehydroepiandrostenedione (DHEA-S), androstenedione, testosterone and oestradiol were recorded.
Consensus statements recommend testing of 17-hydroxyprogesterone, but Dr.
Correlation between androstenedione and 17-hydroxyprogesterone levels in saliva and plasma of patients with congenital adrenal hyperplasia.
27 less than 1% of genetically tested patients had clear diagnosis while BAI do not predict the mutation; 17-hydroxyprogesterone assays may be used but with a low specificity.
Steroid hormones (androstenedione, 17-hydroxyprogesterone, female testosterone, DHEAS, dihydrotestosterone);
Hormonal analyses included: thyroid stimulating hormone, dehydroepiandrosterone sulfate (DHEAS), prolactin (PRL), luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2), 17-hydroxyprogesterone (17-OHP), androstenedione (A), free testosterone (fT), total testosterone (tT), insulin, and sex hormone binding globulin (SHBG) levels.
Simultaneous radioimmunoassay of progesterone, androst-4-enedione, pregnenolone, dehydroepiandrosterone and 17-hydroxyprogesterone in specific regions of human brain.
4) Thyroid functions, luteinizing hormone (LH)/follicle-stimulating hormone (FSH) ratio, and prolactin, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, and total testosterone levels were assessed for all patients.
The effects on preterm birth rates of maternal 17-hydroxyprogesterone use, a preterm birth prevention strategy that increased during this period (6), were not examined and the effects of maternal age on spontaneous, medically indicated, early, or late preterm births were not assessed.
The patient was started on stress-dose steroids after measurement of baseline adrenocorticotropic hormone (ACTH), renin, aldosterone, 17-hydroxyprogesterone (17-OHP), and cortisol.